Gefitinib-induced paronychia: Response to autologous platelet-rich plasma

Archives of Dermatology

Volumn 148, Issue 12, 2012, Pages 1399-1402

  Kwon, Soon Hyo ^a   Choi, Jae Woo ^a   Hong, Jong Soo ^a   Byun, Sang Young ^a   Park, Kyoung Chan ^a   Youn, Sang Woong ^a   Huh, Chang Hun ^a   Na, Jung Im ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CEFRADINE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CISPLATIN; DOXYCYCLINE; GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADVERSE OUTCOME; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; DRUG INDUCED DISEASE; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PARONYCHIA; PRIORITY JOURNAL; THROMBOCYTE RICH PLASMA; TREATMENT FAILURE; TREATMENT RESPONSE; CASE REPORT; CHEMICALLY INDUCED; LUNG NEOPLASMS;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; PARONYCHIA; PLATELET-RICH PLASMA; QUINAZOLINES;

EID: 84871391124     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.3022     Document Type: Article

References (23)

1. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55(4):657-670. (Pubitemid 44436627)
2. Jost M, Kari C, Rodeck U. The EGF receptor: an essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;10(7):505-510.
3. Lee MW, Seo CW, Kim SW, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol. 2004;84(1):23-26.
4. Chang GC, Yang TY, Chen KC, Yin MC,Wang RC, Lin YC. Complications of therapy in cancer patients: case 1: paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22(22):4646-4648.
5. Dainichi T, Tanaka M, Tsuruta N, Furue M, Noda K. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology. 2003;207(3):324-325. (Pubitemid 37329208)
6. Nakano J, Nakamura M. Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Dermatol. 2003;30(3):261-262. (Pubitemid 36417562)
7. Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med. 2010;83(1):1-9.
8. Rozman P, Bolta Z. Use of platelet growth factors in treating wounds and soft-tissue injuries. Acta Dermatovenerol Alp Panonica Adriat. 2007;16(4):156-165.
9. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004;114(6):1502-1508. (Pubitemid 40361959)
10. Na JI, Choi JW, Choi HR, et al. Rapid healing and reduced erythema after ablative fractional carbon dioxide laser resurfacing combined with the application of autologous platelet-rich plasma. Dermatol Surg. 2011;37(4):463-468.
11. Kazakos K, Lyras DN, Verettas D, Tilkeridis K, Tryfonidis M. The use of autologous PRP gel as an aid in the management of acute trauma wounds. Injury. 2009;40(8):801-805.
12. Driver VR, Hanft J, Fylling CP, Beriou JM; Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52(6):68-70, 72, 74.
13. Akingboye AA, Giddins S, Gamston P, Tucker A, Navsaria H, Kyriakides C. Application of autologous derived-platelet rich plasma gel in the treatment of chronic wound ulcer: diabetic foot ulcer. J Extra Corpor Technol. 2010;42(1):20-29.
14. Hom DB, Linzie BM, Huang TC. The healing effects of autologous platelet gel on acute human skin wounds. Arch Facial Plast Surg. 2007;9(3):174-183.
15. Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br. 2009;91(8):987-996.
16. Eppley BL, Pietrzak WS, Blanton M. Platelet-rich plasma: a review of biology and applications in plastic surgery. Plast Reconstr Surg. 2006;118(6):147e-159e. doi: 10.1097/01.prs.0000239606.92676.cf. (Pubitemid 44610374)
17. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008;58(4):545-570. (Pubitemid 351375051)
18. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144(6):1169-1176. (Pubitemid 34204207)
19. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16(9):1425-1433. (Pubitemid 41222414)
20. Shu KY, Kindler HL, Medenica M, Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol. 2006;154(1):191-192. (Pubitemid 43381348)
21. Mishra A, Tummala P, King A, et al. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods. 2009;15(3):431-435.
22. Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther. 2008;15(10):711-715. (Pubitemid 351627354)
23. Liu YS, Zhou YS, Zhu SS. Effect of in vitro storage on the biological activity of human platelet-rich plasma [in Chinese]. Beijing Da Xue Xue Bao. 2008;40(1):34-38